Øystein Fløtten

Associate Professor

Academic article

Show author(s) (2022). Trajectory of health-related quality of life during the last year of life in patients with advanced non-small–cell lung cancer. Supportive Care in Cancer. 9351-9358.
Show author(s) (2022). Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer. Lung Cancer. 49-57.

Show author(s) (2021). High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. The Lancet Oncology. 321-331.

Show author(s) (2020). Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC. Acta Oncologica.

Show author(s) (2018). Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement. Anticancer Research. 871-876.
Show author(s) (2018). Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small-cell lung cancer: a pooled analysis of two randomized trials. Acta Oncologica. 1574-1579.
Show author(s) (2018). A comparison of CT based measures of skeletal muscle mass and density from the Th4 and L3 levels in patients with advanced non-small-cell lung cancer. European Journal of Clinical Nutrition. 1-8.

Show author(s) (2017). Muscle mass and association to quality of life in non-small cell lung cancer patients. Journal of Cachexia, Sarcopenia and Muscle. 759-767.
Show author(s) (2017). Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet Chemotherapy in Advanced Non-Small-Cell Lung Cancer. Clinical Lung Cancer. e129-e136.

Show author(s) (2016). Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer. Lung Cancer. 9-14.
Show author(s) (2016). Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Annals of Oncology. 1291-1298.
Show author(s) (2016). Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer. Annals of Oncology. 225-232.
Show author(s) (2016). Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. Clinical Nutrition. 1386-1393.
Show author(s) (2016). Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer. Acta Oncologica. 591-597.
Show author(s) (2016). Oral versus intravenous vinorelbine in advanced NSCLC - a retrospective comparison. Cancer Treatment and Research Communications. 15-20.
Show author(s) (2016). Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer. Acta Oncologica. 1349-1354.

Show author(s) (2015). Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer. Lung Cancer. 85-91.

Show author(s) (2013). Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group. British Journal of Cancer. 1467-1475.

Show author(s) (2012). Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. British Journal of Cancer. 442-447.
Show author(s) (2012). A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer. Lung Cancer. 63-69.

Show author(s) (2010). Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. European Journal of Cancer. 2225-2234.

Show author(s) (2009). A prospective phase II study: High-dose pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung Cancer. 88-93.

Letter to the editor

Show author(s) (2022). Characteristics and survival of patients with non-small cell lung cancer treated with immune-checkpoint inhibitors in the real-world: experiences from Bergen, Norway. Acta Oncologica. 814-818.

Doctoral dissertation

Show author(s) (2019). Simplifying Treatment of Advanced Non-small Cell Lung Cancer. Regimen, Route of Administration, and Patients' Preferences .

Abstract

Show author(s) (2015). Survival of patients with N3 lymph node disease in a cohort with limited disease small-cell lung cancer receiving concurrent chemoradiotherapy. Journal of Thoracic Oncology. s744.
Show author(s) (2015). Reduction in tumor size after the first course of cisplatin/etoposide (PE) in limited disease small-cell lung cancer (LD SCLC). Journal of Clinical Oncology.
Show author(s) (2015). Associations between Comorbidity, Treatment Toxicity and Overall Survival in Limited Disease Small-Cell Lung Cancer (LD-SCLC). Journal of Thoracic Oncology. s744.

Show author(s) (2012). Randomized phase II trial comparing two schedules of thoracic radiotherapy (TRT) in limited disease small-cell lung cancer (LD SCLC). Journal of Clinical Oncology. 1 pages.

Show author(s) (2011). Randomized Phase Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases from Lung Cancer: The MENZA Study. European Journal of Cancer. 640-640.

Poster

Show author(s) (2018). Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small- cell lung cancer.

Show author(s) (2015). Association between comorbidity, treatment toxicity and overall survival in limited disease small-cell lung cancer.

Show author(s) (2012). Phase II Trial Comparing Two Schedules of Thoracic Radiotherapy in Limited Disease Small-Cell Lung Cancer.

Show author(s) (2011). Randomized Phase Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases from Lung Cancer: The MENZA Study.

Show author(s) (2010). Phase III study comparing vinorelbine-gemcitabine with vinorelbine-carboplatin as first-line chemotherapy of advanced NSCLC: A Norwegian Lung Cancer Study Group trial.
Show author(s) (2010). Phase III study comparing vinorelbine-gemcitabine with vinorelbine-carboplatin as first-line chemotherapy of advanced NSCLC: A Norwegian Lung Cancer Study Group trial.

Academic literature review

Show author(s) (2017). Implementation of lung cancer CT screening in the Nordic countries. Acta Oncologica. 1249-1257.

Website (informational material)

Show author(s) (2013). Nasjonal handlingsplan for lungekreft (for Helsedirektoratet, HD og Norwegian Lung Cancer Group, NLCG) - utredning og behandling (utredningskapittelet).